Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Unexpected Positive Cultures in Rotator Cuff Revision Surgery

NCT06257979 · tracked via the Priya Life Science France tracker
Sponsor
Phase
Not applicable
Started
2024-02-27
Last updated
2024-06-18

Condition(s) studied

Rotator Cuff Repair

Investigational drug(s) / intervention(s)

This study is with minimal risk and minimal constraints due to the addition of questionnaires

This study is with minimal risk and minimal constraints due to the addition of questionnaires: In this study, the specific procedures compared to routine care are : * Considering the addition of questionnaires, this study will be prospective. Due to the use of bacteriological samples, it is considered as a minimal-risk research. * The research procedure involves a bacteriological analysis of operative elements (sutures placed during the first intervention, the product of tendon debridement, and the subacromial bursa (cleaning product)) used during the re-intervention. These usually discarded operative samples are collected for bacteriological analysis. * Antibiotic treatment cannot be prescribed immediately after the surgery and during the first month following this re-intervention (time for biofilm formation). As per the protocol, even a positive sample should not lead to the initiation of systematic antibiotic therapy. In the case of identification of a pathogenic microorganism, antibiotic therapy will be prescribed, leading to discontinuation of the study.

Study summary

In the context of rotator cuff re-intervention, the impact of Unexpected Positive Cultures (UPC) is not documented, and their management has not been studied, particularly regarding indications for antibiotic therapy, which is currently not a consensus.

A prospective interventional study will be implemented to compare the results of non-randomized patient samples, whether positive or negative, taken during rotator cuff re-intervention. The objective is to assess whether these samples do not affect clinical outcomes and tendon healing rates.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient, male or female, aged 18 or over * Patient requiring re- intervention for Rotator Ruff Revision Surgery for non-healing of the same tendons after a first intervention (delay \<2 years) * Patient requiring arthroscopy * Patient having had realized a MRI of the shoulder in the 6 previous months * Affiliate participant or beneficiary of a social security scheme * Participant having been informed and not having objected to the use of their data Exclusion Criteria: * Patient with at least one clinical sign of infection (fever, redness) * Patient with a new distant rupture on a healed cuff (\> 3 years) * Patient with a history of shoulder surgery other than initial Rotator Ruff Surgery * Patient having received antibiotic treatment in the 2 weeks preceding inclusion * Participant in another research * Participant in a period of exclusion from another research still in progress at the time of inclusion * Protected participant: an adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision * Pregnant, breastfeeding or parturient woman * Participant hospitalized without consent

Primary outcome measure(s)

  • Compare the functional recovery of the shoulder at one year after iterative repair of non-healing rotator cuff between patients with unexpected positive cultures and patients with negative results. — at Month 1, Month 3, Month 6 and 1 Year after the re-intervention
    Compare the functional recovery (Yes/No), at one year after iterative repair of non-healing rotator cuff between patients with unexpected positive cultures and patients with negative results using the Constant Score.
  • Compare the 2 groups on tendon healing, after iterative repair of non-healing of the rotator cuff — at Month 1, Month 3, Month 6 and 1 Year after the re-intervention
    Compare the 2 groups on tendon healing (Yes/No), after iterative repair of non-healing of the rotator cuff using the Constant Score.
  • Compare the 2 groups on the occurrence of post-operative complications, after iterative repair of non-healing of the rotator cuff — up to one year after the re-intervention
    Compare the 2 groups on the occurrence of post-operative complications (Yes/No), after iterative repair of non-healing of the rotator cuff and list them
  • Compare the 2 groups on the patient's other functional scores — at Month 1, Month 3, Month 6 and 1 Year after the re-intervention
    Compare the 2 groups on the patient's other functional scores such as SSV and ASES questionnaries
  • Describe the pathogenic germs found in the positive cultures — at Month 1 after the re-intervention
    List of pathogenic germs found in the positive samples

Trial sites (8)

FacilityCityRegionStatus
Hôpital privé La Châtaigneraie ELSAN Beaumont France Not Yet Recruiting
Hôpital privé Saint-Martin Caen France Not Yet Recruiting
Clinique Louis Pasteur Essey-lès-Nancy France Not Yet Recruiting
Santy-Lyon-Ramsay Lyon France Not Yet Recruiting
Clinique d'occitanie ELSAN Muret France Not Yet Recruiting
ICR-Kantys Nice France Not Yet Recruiting
Santé Atlantique ELSAN Saint-Herblain France Not Yet Recruiting
Clinique de l'Orangerie Strasbourg France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06257979 on ClinicalTrials.gov ↗ ← All trials in France